Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Methallylescaline

From Wikipedia, the free encyclopedia

Pharmaceutical compound
Methallylescaline
Clinical data
Other namesMAL; 4-Methylallyloxy-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-methylallyloxyphenethylamine; 4-Methylallyl-desmethylmescaline; MAD
Routes of
administration
Oral[1]
Drug classSerotonin receptor modulator;Serotonin 5-HT2A receptor agonist;Serotonergic psychedelic;Hallucinogen
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Onset of action≤1 hour[1]
Duration of action12–16 hours[1]
Identifiers
  • 2-{3,5-Dimethoxy-4-[(2-methylprop-2-en-1-yl)oxy]phenyl}ethan-1-amine
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC14H21NO3
Molar mass251.326 g·mol−1
3D model (JSmol)
  • CC(=C)COc1c(cc(cc1OC)CCN)OC
  • InChI=1S/C14H21NO3/c1-10(2)9-18-14-12(16-3)7-11(5-6-15)8-13(14)17-4/h7-8H,1,5-6,9,15H2,2-4H3 checkY
  • Key:FOXJFBFFGULACD-UHFFFAOYSA-N checkY
  (verify)

Methallylescaline (MAL), also known as4-methylallyloxy-3,5-dimethoxyphenethylamine, is apsychedelic drug of thephenethylamine andscaline families related tomescaline.[1][3] It is takenorally.[1][3]

The drug acts as aserotonin5-HT2 receptoragonist, including of the serotonin5-HT2A receptor.[4][5] It is closelystructurally related to mescaline and to other scalines likeescaline andallylescaline.[5]

Methallylescaline was first described byAlexander Shulgin in his 1991 bookPiHKAL (Phenethylamines I Have Known and Loved).[3][1] It was encountered as a noveldesigner drug by 2013.[6][7][8]

Use and effects

[edit]

In his bookPiHKAL (Phenethylamines I Have Known and Loved),Alexander Shulgin lists the dose range of methallylescaline as 40 to 65 mg and itsduration as 12 to 16 hours.[1][9][10] As such, its dose range is relatively narrow.[1][9][10] Moreover, the drug has been reported to have an unusually steepdose–response curve, such that a small increase in dose can result in an unexpectedly large increase in effects.[11][12] Methallylescaline has about 6 times thepotency of mescaline, which has a much higher listed dose range of 200 to 400 mg.[9][10][1] Itsonset is within 1 hour and peak effects occur within 2 hours.[1]

Shulgin has described methallylescaline as a "mixed bag" in terms ofexperience reports.[1] Its effects have been reported to includeclosed-eye visuals, "visual theater",open-eye visuals includingvisual distortions, visual depth and movement effects,kaleidoscopicneon colors,watercolors,fantasy,mental imagery,feelings of unreality, easy childhoodmemory recall, self-connectedness,eroticism, initialdiscomfort,overload, feeling overwhelmed, shades of possibleamnesia, loss of contact, extremerestlessness,trouble sleeping, and enhanceddreams.[1] It was also reported to produce quite strongbody effects,diuretic effects, and slightlyreduced heart rate.[1] Some found it unpleasant and said that they would not repeat the experience, whereas others were impressed by it, found it enjoyable, and called it "beautiful".[1] Many expressed that the dose they tried was too strong for them and that a lower dose would be better.[1] Methallylescaline has been described as having relatively morevisual imagery than otherscalines likecyclopropylmescaline andallylescaline.[1]

Others have noted that methallylescaline has strongvisual effects, as well as prominentnausea,vomiting, andbody load, including feeling "overstimulated.[11] The drug is frequently compared tomescaline.[11]

Interactions

[edit]
See also:Psychedelic drug § Interactions, andTrip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]
Methallylescaline activities
TargetAffinity (Ki, nM)
5-HT1A5,100–>10,000
5-HT1B>10,000
5-HT1D2,754
5-HT1E>10,000
5-HT1FND
5-HT2A72–955 (Ki)
8.5–891 (EC50Tooltip half-maximal effective concentration)
19–110% (EmaxTooltip maximal efficacy)
5-HT2B110 (Ki)
4.9–>10,000 (EC50)
32–103% (
Emax)
5-HT2C5.1–520 (Ki)
1.8–331 (EC50)
75–102% (
Emax)
5-HT3>10,000
5-HT4ND
5-HT5A>10,000
5-HT6>10,000
5-HT7>10,000
α1Aα1D>10,000
α2A550–1,500
α2B,α2C>10,000
β1β3>10,000
D1D5>10,000
H1H4>10,000
M1M5>10,000
TAAR11,000 (Ki) (rat)
3,900 (Ki) (mouse)
(EC50) (rodent)
>10,000 (
EC50) (human)
I1ND
σ1>10,000
σ25,248
SERTTooltip Serotonin transporter>10,000 (Ki)
ND (IC50Tooltip half-maximal inhibitory concentration)
NETTooltip Norepinephrine transporter>10,000 (Ki)
ND (IC50)
DATTooltip Dopamine transporter>10,000 (Ki)
ND (IC50)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified.Refs:[4][5][13][14]

Methallylescaline acts as apotentagonist of theserotonin5-HT2A,5-HT2B, and5-HT2C receptors, among other actions.[4][5][13][14] It was inactive serotonin 5-HT2B receptor agonist in one study,[5] but was a potent agonist in another study.[4] The comprehensivereceptor interactions of methallylescaline have been studied.[4]

The drug produces thehead-twitch response (HTR), a behavioral proxy ofpsychedelic effects, in rodents.[14] Surprisingly, the HTR induced by methallylescaline was blocked by theselective serotonin 5-HT2C receptorantagonistSB-242084 but not by the serotonin 5-HT2A receptor antagonistketanserin.[14]

In addition to its psychedelic-like effects, methallylescaline produceshyperlocomotion (astimulant-like effect),conditioned place preference (CPP; arewarding effect), and modestself-administration (areinforcing effect) in rodents, among other effects.[15]

Methallylescaline, along withBOD andDOI, has been reported to produceserotonergic neurotoxicity in rodents at high doses given repeatedly.[14] Other psychedelics have also been found to produce neurotoxicity inpreclinical research.[16][17][18]

Pharmacokinetics

[edit]

Themetabolism of methallylescaline has been studied.[19][20]

Chemistry

[edit]

Methallylescaline, also known as 4-methylallyloxy-3,5-dimethoxyphenethylamine, is asubstituted phenethylamine andscaline.[1][3][9][10] It is asyntheticderivative ofmescaline (3,4,5-trimethoxyphenethylamine) with amethallyloxygroup instead ofmethoxy group at the 4 position.[1][3][9][10]

Synthesis

[edit]

Thechemical synthesis of methallylescaline has been described.[1]

Analogues

[edit]

Analogues of methallylescaline includemescaline,escaline,allylescaline, andcyclopropylmescaline, among others.[1][3][9][10][21] Some other analogues include3C-MAL,2C-T-3,2C-O-3, andMMALM.[1][3][21]

History

[edit]

Methallylescaline was first described in the literature byAlexander Shulgin in his 1991 bookPiHKAL (Phenethylamines I Have Known and Loved).[3][1][9] It was first tried by Shulgin in 1981 and itshallucinogenic effects were discovered by him in 1982.[22][10] The drug has an entry inPiHKAL, but not in Shulgin's 2011 bookThe Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds.[3] It was encountered as a noveldesigner drug inEurope by 2013.[6][7][8] Methallylescaline'spharmacology was described byMatthias Liechti andDaniel Trachsel and colleagues in 2021.[5] Discussion of methallylescaline online began increasing in late 2023.[11]

Society and culture

[edit]

Names

[edit]

Alexander Shulgin described the name ofmethallylescaline (MAL) as "completely unsound".[1] This was because there was no union of amethallyl group withescaline.[1] Instead, methallylescaline ismescaline with a 2-propene group attached to themethyl of themethoxy group at the 4 position.[1] However, Shulgin expressed that there is no way of naming the compound in that manner.[1] The only corresponding proper name would be4-methylallyldesmethylmescaline (MAD).[1] However, Shulgin found the acronymMAD to be disagreeable and ultimately preferredMAL.[1]

Legal status

[edit]

Canada

[edit]

Methallylescaline is not acontrolled substance inCanada as of 2025.[23]

Sweden

[edit]

Methallylescaline is illegal in Sweden as of 26 January 2016.[24]

United States

[edit]

Methallylescaline is not explicitly scheduled under theControlled Substances Act.[25] However, due to its structural similarities withmescaline, it could potentially be prosecuted under theFederal Analogue Act if sold for human consumption.

See also

[edit]

References

[edit]
  1. ^abcdefghijklmnopqrstuvwxyzaaab"Methallylescaline".PiHKAL.
  2. ^Anvisa (2023-07-24)."RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese).Diário Oficial da União (published 2023-07-25).Archived from the original on 2023-08-27. Retrieved2023-08-27.
  3. ^abcdefghiShulgin A, Manning T, Daley PF (2011)."#91. Mescaline".The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley, CA: Transform Press. pp. 212–225 (217).ISBN 978-0-9630096-3-0.OCLC 709667010.[...] Homologues and Analogues [...] Name: MAL. CAS #: [207740-41-8]. Ref: (30,31). [...] (30) Synthesis (Shulgin and Shulgin, 1991). (31) Orally active in humans at 40-65 mg; duration 12-16 hours (Shulgin and Shulgin, 1991).
  4. ^abcdeJain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, et al. (October 2025). "The polypharmacology of psychedelics reveals multiple targets for potential therapeutics".Neuron.113 (19): 3129–3142.e9.doi:10.1016/j.neuron.2025.06.012.PMID 40683247.
  5. ^abcdefKolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2021)."Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines".Frontiers in Pharmacology.12 794254.doi:10.3389/fphar.2021.794254.PMC 8865417.PMID 35222010.
  6. ^abKing LA (2014). "New phenethylamines in Europe".Drug Testing and Analysis.6 (7–8):808–818.doi:10.1002/dta.1570.PMID 24574327.
  7. ^ab"EMCDDA–Europol 2013 Annual Report on the implementation of Council Decision 2005/387/JHA".www.euda.europa.eu. 2 July 2024. Retrieved9 October 2025.
  8. ^abCoelho Neto J (July 2015). "Rapid detection of NBOME's and other NPS on blotter papers by direct ATR-FTIR spectrometry".Forensic Science International.252:87–92.doi:10.1016/j.forsciint.2015.04.025.PMID 25965305.
  9. ^abcdefgJacob P, Shulgin AT (1994)."Structure-activity relationships of the classic hallucinogens and their analogs"(PDF).NIDA Research Monograph.146:74–91.PMID 8742795. Archived fromthe original(PDF) on August 5, 2023.
  10. ^abcdefgShulgin AT (2003)."Basic Pharmacology and Effects". In Laing RR (ed.).Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137.ISBN 978-0-12-433951-4. Retrieved1 February 2025.
  11. ^abcd"Weekly Briefing Issue 181".National Drug Early Warning System (NDEWS). 10 May 2024. Retrieved5 January 2026.
  12. ^"SATA Early Warning System of the Americas". Archived fromthe original on 2025-06-19.[United States National Drug Early Warning System (NDEWS)] issued an alert about the substance methallylescaline, a synthetic analog of mescaline and a 5-HT receptor agonist. Discussions in online forums often warn of methallylescaline's steep dose-response curve, where small dosage changes can dramatically alter the experience. Some of the effects discussed are nausea and "body load". Those who experiment with polysubstance use, combine methallylescaline with other substances, such as etizolam.
  13. ^abWang S, Zhu A, Paudel S, Jang CG, Lee YS, Kim KM (March 2023)."Structure-Activity Relationship and Evaluation of Phenethylamine and Tryptamine Derivatives for Affinity towards 5-Hydroxytryptamine Type 2A Receptor".Biomolecules & Therapeutics.31 (2):176–182.doi:10.4062/biomolther.2022.096.PMC 9970836.PMID 36224112.
  14. ^abcdeCustodio RJ, Ortiz DM, Lee HJ, Sayson LV, Kim M, Lee YS, et al. (July 2025). "Serotonin 2C receptors are also important in head-twitch responses in male mice".Psychopharmacology.242 (7):1585–1605.doi:10.1007/s00213-023-06482-9.PMID 37882810.
  15. ^Custodio RJ, Sayson LV, Botanas CJ, Abiero A, Kim M, Lee HJ, et al. (September 2020). "Two newly-emerging substituted phenethylamines MAL and BOD induce differential psychopharmacological effects in rodents".Journal of Psychopharmacology.34 (9):1056–1067.doi:10.1177/0269881120936458.PMID 32648801.
  16. ^Rudin D, Liechti ME, Luethi D (September 2021). "Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics".Experimental Neurology.343 113778.doi:10.1016/j.expneurol.2021.113778.PMID 34090893.
  17. ^Capela JP, Ruscher K, Lautenschlager M, Freyer D, Dirnagl U, Gaio AR, et al. (2006). "Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor-dependent and potentiated under hyperthermia".Neuroscience.139 (3):1069–1081.doi:10.1016/j.neuroscience.2006.01.007.PMID 16504407.
  18. ^Capela JP, Carmo H, Remião F, Bastos ML, Meisel A, Carvalho F (June 2009). "Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview".Molecular Neurobiology.39 (3):210–271.doi:10.1007/s12035-009-8064-1.PMID 19373443.To further corroborate the fact that MDMA agonistic properties at the 5-HT2A receptor could produce neuronal death, DOI, a prototypical agonist of that receptor was added to cortical neurons [289]. DOI (10 to 100 μM for 24 or 48 h) also induced a dose- and time-dependent apoptotic cortical neuronal apoptosis, which was attenuated by ketanserin and R-96544 [289]. Ketanserin and R-96544 are competitive selective 5-HT2A receptor antagonists and only attenuated MDMA-induced cortical neurodegeneration. However, an antibody raised against the 5-HT2A-receptor, an "irreversible" non-competitive 5-HT2A receptor blocker, prevented almost completely MDMA- and DOI-induced cortical neurotoxicity [289, 290]. Neuronal apoptosis mediated by MDMA is accompanied by activation of caspase 3, which could be blocked by the antibody raised against the 5-HT2A receptor [290]. Therefore, it is likely that DOI- and MDMA-induced neuronal apoptosis arises from direct stimulation of the 5-HT2A receptor [289, 290].
  19. ^Tang Y, Xu L, Guo Z, Zhao J, Xiao Y, Xiang P, et al. (June 2025). "Metabolism study of two phenethylamine - derived new psychoactive substances using in silico, in vivo, and in vitro approaches".Archives of Toxicology.99 (6):2367–2378.doi:10.1007/s00204-025-04010-6.PMID 40064698.
  20. ^Kim S, Kim JH, Kim DK, Lee J, In S, Lee HS (30 September 2018). "In vitro Metabolism of Methallylescaline in Human Hepatocytes Using Liquid Chromatography-High Resolution Mass Spectrometry".Mass Spectrometry Letters.9 (3):86–90.doi:10.5478/MSL.2018.9.3.86.
  21. ^abTrachsel D, Lehmann D, Enzensperger C (2013).Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag.ISBN 978-3-03788-700-4.OCLC 858805226. Archived fromthe original on 21 August 2025.
  22. ^Alexander Shulgin (1981),Pharmacology Lab Notes #4(PDF)
  23. ^"Controlled Drugs and Substances Act".Department of Justice Canada. Retrieved19 January 2026.
  24. ^"31 nya ämnen kan klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. November 2015.
  25. ^Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026)(PDF),United States: U.S.Department of Justice:Drug Enforcement Administration (DEA): Diversion Control Division, January 2026

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=Methallylescaline&oldid=1334199401"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp